Horizon Discovery is a provider of research tools to support the development of personalized medicines.
The Company? proprietary virally-mediated gene-engineering technology, GENESIS? enables any endogenous gene in a human cell-line to be altered quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes. Using GENESIS, Horizon Discovery has developed X-MAN?(Gene-X; Mutant And Normal) cell models, which are the world? first source of genetically-defined and patient-relevant human cell lines.
The Company? broad panel of over 350 different X-MAN cell lines, which have been referred to as ?atients-in-a-test-tube,?accurately model the disease-causing mutations in cancer patients. The X-MAN cell lines are being used by academic and industry leaders to identify the effect of individual mutations on drug activity, patient responsiveness and resistance, and to successfully predict which patient sub-groups will respond to currently-available and future drug treatments. This supports the design of shorter, more focused clinical trials, making it possible to identify the ?ight drugs?for the ?ight patients?based upon the unique genetic mutations that define their disease.
Founded in 2007 by Dr Chris Torrance and Professor Alberto Bardelli, and with headquarters in Cambridge, UK, the company builds on a long heritage in gene-engineering, cancer research and translational medicine, and draws on intellectual property and know-how from the University of Washington, the Johns Hopkins University, the University of Maryland, the University of Minnesota and the Department of Oncological Sciences at the University of Torino Medical School. Over 400 scientific papers relating to the use of X-MAN cell line pairs generated using GENESIS have been published, and the technology has won numerous awards including; Medical Futures Innovation Award for Cancer (2008), UK iaward of the Year (2009), East of England Killer Technology (2009) and East of England Young Company of Year (2010).